New drug aims to calm immune attacks on kidneys
NCT ID NCT06983028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure changes in protein in the urine, a key sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atacicept
What this could lead to
If successful, atacicept could offer a new treatment option to reduce protein leakage and preserve kidney function in people with autoimmune kidney diseases.
What could go wrong
This is an early Phase 2 trial with a moderate size of 250 people. It may not show clear benefit, and side effects or lack of efficacy could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vera Therapeutics
RECRUITINGBrisbane, California, 94005, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••